The Effectiveness of Myo-Inositol and D-Chiro Inositol Treatment in Type 2 Diabetes
Open accessAbstract
Inositol has been used as a supplement in treating several pathologies such as PCOS, metabolic syndrome, and gestational diabetes. Both myo-inositol and its isomer d-chiro-inositol showed insulin mimetic effects in conditions of insulin resistance. Type 2 diabetes (T2DM) is a condition typically caused by insulin resistance. There is a lack of evidence of inositol use in T2DM. We evaluated the effectiveness and safety of myo-inositol and d-chiro-inositol treatment in T2DM. This was a pilot study involving a consecutive sample of patients with T2DM with suboptimal glycemic control (HbA1c 7.0–10.0%) already treated with glucose-lowering agents. Patients (23.1% males, mean age of 60.8 ± 11.7 years) took for three months a combination of myo-inositol (550 mg) and d-chiro-inositol (13.8 mg) orally twice a day as add-on supplement to their glucose-lowering drugs. Possible occurrence of side effects was investigated. After three months of treatment fasting blood glucose ( 192.6 ± 60.2 versus 160.9 ± 36.4 ; p = 0.02 ) and HbA1c levels ( 8.6 ± 0.9 versus 7.7 ± 0.9 ; p = 0.02 ) significantly decreased compared to baseline. There was no significant difference in blood pressure, lipid profile, and BMI levels. None of the participants reported side effects. In conclusion, a supplementation with a combination of myo- and d-chiro-inositol is an effective and safe strategy for improving glycemic control in T2DM.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In that pilot study, there was no significant difference in blood pressure, lipid profile, and BMI levels.
“There was no significant difference in blood pressure, lipid profile, and BMI levels [82].”
From From Prediabetes to Type 2 Diabetes Mellitus in Women with Polycystic Ovary Syndrome: Lifestyle and Pharmacological Management (2020) · cites this paper as [82]
In a pilot study of 20 subjects with T2D and suboptimal glycemic control already treated with glucose-lowering agents, three months of oral myo-inositol plus d-chiro-inositol in a 40:1 ratio as add-on significantly decreased fasting blood glucose and HbA1c levels compared to baseline.
“After three months of treatment, fasting blood glucose and HbA1c levels significantly decreased compared to the baseline.”
From From Prediabetes to Type 2 Diabetes Mellitus in Women with Polycystic Ovary Syndrome: Lifestyle and Pharmacological Management (2020) · cites this paper as [82]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490 · see citing works
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · see citing works
European guidelines on cardiovascular disease prevention in clinical practice: executive summary
Graham, I., Atar, D., Borch‐Johnsen, K., Boysen, G., Burell, G. K., Cífková, R., Dallongeville, J., Backer, G. D., Ebrahim, S. B. J., Gjelsvik, B., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm316 · Cited by 3,840 · see citing works
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834 · see citing works
Mechanisms for Insulin Resistance: Common Threads and Missing Links
Samuel, V. T., & Shulman, G. I. (2012) · Cell · doi:10.1016/j.cell.2012.02.017 · Cited by 2,294 · see citing works
Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients.
Shichiri, M., Kishikawa, H., Ohkubo, Y., & Wake, N. (2000) · PubMed · Cited by 727 · see citing works
Potential role and therapeutic interests of myo-inositol in metabolic diseases
Croze, M. L., & Soulage, C. O. (2013) · Biochimie · doi:10.1016/j.biochi.2013.05.011 · Cited by 580 · see citing works
D-Chiro-Inositol – Its Functional Role in Insulin Action and its Deficit in Insulin Resistance
Larner, J. (2002) · International Journal of Experimental Diabetes Research · doi:10.1080/15604280212528 · Cited by 279 · see citing works
Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials
Unfer, V., Carlomagno, G., Dante, G., & Facchinetti, F. (2012) · Gynecological Endocrinology · doi:10.3109/09513590.2011.650660 · Cited by 201 · see citing works
Efficacy of metformin in the treatment of NIDDM. Meta-analysis.
Johansen, K. B. (1999) · Diabetes Care · doi:10.2337/diacare.22.1.33 · Cited by 186 · see citing works
Liu, S. ‐., Tu, Y. ‐., Chien, M. ‐., & Chien, K. ‐. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01606.x · Cited by 180 · see citing works
D’Anna, R., Scilipoti, A., Giordano, D., Caruso, C., Cannata, M. L., Interdonato, M. L., Corrado, F., & Benedetto, A. D. (2013) · Diabetes Care · doi:10.2337/dc12-1371 · Cited by 170 · see citing works
Corrado, F., D’Anna, R., Vieste, G. D., Giordano, D., Pintaudi, B., Santamaria, A., & Benedetto, A. D. (2011) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03284.x · Cited by 164 · see citing works
Self-citationSun, T.-H., Heimark, D. B., Nguygen, T., Nadler, J. L., & Larner, J. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00313-3 · Cited by 144 · see citing works
Myo-inositol Supplementation for Prevention of Gestational Diabetes in Obese Pregnant Women
D’Anna, R., Benedetto, A. D., Scilipoti, A., Santamaria, A., Interdonato, M. L., Petrella, E., Neri, I., Pintaudi, B., Corrado, F., & Facchinetti, F. (2015) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000000958 · Cited by 133 · see citing works
Self-citationWorldwide Experience of Metformin as an Effective Glucose-lowering Agent: A Meta-analysis
Campbell, I. W., & Howlett, H. C. S. (1995) · Diabetes/Metabolism Reviews · doi:10.1002/dmr.5610110509 · Cited by 122 · see citing works
Santamaria, A., Benedetto, A. D., Petrella, E., Pintaudi, B., Corrado, F., D’Anna, R., Neri, I., & Facchinetti, F. (2015) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.3109/14767058.2015.1121478 · Cited by 116 · see citing works
Self-citationOrtmeyer, H. K., Huang, L. C., Zhang, L., Hansen, B. C., & Larner, J. (1993) · Endocrinology · doi:10.1210/endo.132.2.8425484 · Cited by 113 · see citing works
Crawford, T. J., Crowther, C. A., Alsweiler, J. M., & Brown, J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011507.pub2 · Cited by 98 · see citing works
In vivo conversion of [3H]myoinositol to [3H]chiroinositol in rat tissues.
Pak, Y., Huang, L. C., Lilley, K., & Larner, J. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)41870-4 · Cited by 95 · see citing works
Dinicola, S., Chiu, T. T. Y., Unfer, V., Carlomagno, G., & Bizzarri, M. (2014) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.362 · Cited by 95 · see citing works
Giordano, D., Corrado, F., Santamaria, A., Quattrone, S., Pintaudi, B., Di Benedetto, A., & D'Anna, R. (2011) · Menopause · doi:10.1097/gme.0b013e3181e8e1b1 · Cited by 89 · see citing works
Self-citationSudchada, P., Saokaew, S., Sridetch, S., Incampa, S., Jaiyen, S., & Khaithong, W. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.05.027 · Cited by 80 · see citing works
One-year effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome
Santamaria, A., Giordano, D., Corrado, F., Pintaudi, B., Interdonato, M. L., Vieste, G. D., Benedetto, A. D., & D’Anna, R. (2011) · Climacteric · doi:10.3109/13697137.2011.631063 · Cited by 70 · see citing works
Self-citationUpdates on the myo-inositol plus D-chiro-inositol combined therapy in polycystic ovary syndrome
Unfer, V., & Porcaro, G. (2014) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2014.925795 · Cited by 67 · see citing works
Comparison of different drugs as add-on treatments to metformin in type 2 diabetes: A meta-analysis
Monami, M., Lamanna, C., Marchionni, N., & Mannucci, E. (2007) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2007.08.024 · Cited by 58 · see citing works
Ortmeyer, H. K. (1996) · Obesity Research · doi:10.1002/j.1550-8528.1996.tb00271.x · Cited by 51 · see citing works
Agostini, R., Rossi, F., & Pajalich, R. (2006) · PubMed · Cited by 26 · see citing works
Lubin, V., Shojai, R., Darmon, P., & Cosson, E. (2016) · Diabetes & Metabolism · doi:10.1016/j.diabet.2016.01.005 · Cited by 21 · see citing works
Myo-inositol for preventing gestational diabetes
Brown, J., Crawford, T. J., Alsweiler, J. M., & Crowther, C. A. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011507 · Cited by 10 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Vitagliano, A., Saccone, G., Cosmi, E., Visentin, S., Dessole, F., Ambrosini, G., & Berghella, V. (2019) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-018-5005-0 · Cited by 74 · see citing works
Facchinetti, F., Appetecchia, M., Aragona, C., Bevilacqua, A., Bezerra Espinola, M. S., Bizzarri, M., D’Anna, R., Dewailly, D., Diamanti-Kandarakis, E., Hernández Marín, I., et al. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1737675 · Cited by 63 · see citing works
Pani, A., Gironi, I., Di Vieste, G., Mion, E., Bertuzzi, F., & Pintaudi, B. (2020) · International Journal of Endocrinology · doi:10.1155/2020/6276187 · Cited by 38 · see citing works
Self-citation
- Authors
- Pintaudi, B., Di Vieste, G., & Bonomo, M.
- Affiliations
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- Diabetes Unit, Cantù Hospital, 20081 Abbiategrasso, Italy
- Corresponding author
- Pintaudi, Basilio
- ORCID
- Pintaudi, Basilio
- Venue
- International Journal of Endocrinology
- Publisher
- Wiley
- Published
- 2016
- Volume
- 2016
- Pages
- 1-5
- ISSN
- 1687-8337 (ISSN-L)
- 1687-8345
- PMC
- PMC5078644
- OpenAlex
- W2530218318
- Cited by
- 117
- References
- 31
- Citations by year
- 2026: 8 · 2025: 10 · 2024: 15 · 2023: 17 · 2022: 14 · 2021: 16 · 2020: 15 · 2019: 10 · 2018: 5 · 2017: 7
- FWCI
- 7.37
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- International Journal of Endocrinology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Natural Antidiabetic Agents Studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- myo-inositol, D-chiro-inositol, type 2 diabetes, inositol supplementation, insulin resistance, glycemic control, HbA1c, fasting blood glucose, adjunctive therapy, antidiabetic drugs, adverse effects
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
